Showing results (21-30 of 53) with videos related to
Sort By:
Pageof 6
Biomed Research International|November 7, 2014
H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1?Roland Haubner, Simone Maschauer, Jürgen Einsiedel, et al.Anticancer Research|April 9, 2013
Design and evaluation of novel radiolabelled VIP derivatives for tumour targetingChristine Rangger, Anna Helbok, Meltem Ocak, et al.Cancer Biotherapy & Radiopharmaceuticals|October 19, 2016
Targeting Gastrointestinal Stromal Tumor with <sup>68</sup>Ga-Labeled Peptides: An In Vitro Study on Gastrointestinal Stromal Tumor-Cell LinesAchim Paulmichl, Dominik Summer, Claudia Manzl, et al.Molecules (Basel, Switzerland)|March 26, 2022
Automated Synthesis of <sup>68</sup>Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor TargetingAnton Amadeus Hörmann, Elisabeth Plhak, Maximilian Klingler, et al.Molecular Pharmaceutics|May 6, 2015
Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD ConjugatesChuangyan Zhai, Dominik Summer, Christine Rangger, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 12, 2018
DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic UseMaximilian Klingler, Dominik Summer, Christine Rangger, et al.Molecular Imaging and Biology|February 25, 2016
Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft TumorsChuangyan Zhai, Gerben M Franssen, Milos Petrik, et al.Pharmaceuticals (Basel, Switzerland)|July 2, 2021
Radiopharmaceutical Formulation and Preclinical Testing of <sup>68</sup>Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical TrialAnton A Hörmann, Maximilian Klingler, Christine Rangger, et al.Pharmaceutics|March 29, 2023
Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2RAnton Amadeus Hörmann, Maximilian Klingler, Christine Rangger, et al.Nanomedicine : Nanotechnology, Biology, and Medicine|June 8, 2011
Targeting properties of peptide-modified radiolabeled liposomal nanoparticlesAnna Helbok, Christine Rangger, Elisabeth von Guggenberg, et al.Pageof 6